share_log

B of A Securities Maintains Buy on Travere Therapeutics, Lowers Price Target to $18

B of A Securities Maintains Buy on Travere Therapeutics, Lowers Price Target to $18

B of A證券維持對Travere Therapeutics的買入評級,將價格目標下調至18美元
Benzinga ·  09/27 07:17  · 評級/大行評級

B of A Securities analyst Greg Harrison maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and lowers the price target from $19 to $18.

美國銀行證券分析師Greg Harrison認爲Travere Therapeutics (納斯達克:TVTX) 值得買入並將目標價從19美元下調至18美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論